News
Vitamin D during pregnancy boosts children’s bone health even at age seven

Children whose mothers took extra vitamin D during pregnancy continue to have stronger bones at age seven, according to new research led by the University of Southampton and University Hospital Southampton (UHS).
Bone density scans revealed that children born to mothers who were given vitamin D supplements during pregnancy have greater bone mineral density in mid-childhood.
Their bones contain more calcium and other minerals, making them stronger and less likely to break.
Researchers say the findings, published in The American Journal of Clinical Nutrition, reinforce the importance of vitamin D supplementation in pregnancy as a public health strategy.
Dr Rebecca Moon, NIHR Clinical Lecturer in Child Health at the University of Southampton led the analysis.
She said: “Our findings show that the benefits of vitamin D supplementation during pregnancy persist into mid-childhood.
“This early intervention represents an important public health strategy. It strengthens children’s bones and reduces the risk of conditions like osteoporosis and fractures in later life.”
Vitamin D regulates the amount of calcium and phosphate in the body – minerals essential for bones, teeth and muscle health.
In 2009, researchers launched the MAVIDOS study, recruiting over 1000 women from Southampton, Oxford and Sheffield.
During their pregnancy, the women were randomly allocated to two groups: One group took an extra 1,000 International Units per day of vitamin D. The other took a placebo tablet each day.
The pregnant women, and the doctors and midwives looking after them, did not know which group they were in.
Previous research assessed the children’s bone health at four years of age and the results showed that the child’s bone mass was greater in children born to mothers who had had vitamin D supplementation during pregnancy compared with those who had not.
In this latest study, the researchers investigated whether the effects on bone health continued into mid-childhood.
The team followed up with 454 children aged six to seven. These children were all born to mothers who took part in Southampton.
The results confirmed that the beneficial effect on children’s bones was similar at ages four and six to seven.
Pregnant women in the UK are now routinely advised to take vitamin D supplements.
The Southampton research team are part of the MRC Lifecourse Epidemiology Centre (MRC LEC) and the NIHR Southampton Biomedical Research Centre (BRC).
The MAVIDOS trial has helped the Southampton researchers understand possible mechanisms linking maternal vitamin D supplementation with offspring bone mass.
In 2018 they demonstrated that the vitamin D supplementation led to changes in the activity of genes forming part of the vitamin D pathway.
In 2022, they found taking the supplements during pregnancy could substantially reduce the chances of babies up to a year old suffering from atopic eczema.
They also observed that pregnant women given extra vitamin D were more likely to have a spontaneous vaginal delivery, or ‘natural’ delivery.
Professor Nicholas Harvey is Director of the University’s MRC Lifecourse Epidemiology Centre, Professor of Rheumatology and Clinical Epidemiology and project lead.
He said: “These findings add to the important knowledge generated through the MAVIDOS trial.
“We extend our heartfelt thanks to all the mothers and children involved. Their contributions have advanced our understanding of vitamin D supplementation and its role in supporting strong and healthy bones.”
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.







